347 related articles for article (PubMed ID: 36672193)
1. Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer.
Yu I; Dakwar A; Takabe K
Cells; 2023 Jan; 12(2):. PubMed ID: 36672193
[TBL] [Abstract][Full Text] [Related]
2. Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions.
Chen JT; Zhou YW; Han TR; Wei JL; Qiu M
Front Immunol; 2023; 14():1269341. PubMed ID: 38022667
[TBL] [Abstract][Full Text] [Related]
3. Transforming the landscape of colorectal cancer treatment with immunotherapy: Evolution and future horizons.
Clerick J; Van Oosterwyck A; Carton S
Cancer Treat Res Commun; 2024; 39():100807. PubMed ID: 38461691
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy.
Yang Y; Meng WJ; Wang ZQ
Front Biosci (Landmark Ed); 2023 Apr; 28(4):69. PubMed ID: 37114536
[TBL] [Abstract][Full Text] [Related]
5. Current advancements and future perspectives of immunotherapy in colorectal cancer research.
Kishore C; Bhadra P
Eur J Pharmacol; 2021 Feb; 893():173819. PubMed ID: 33347822
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
7. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
Picard E; Verschoor CP; Ma GW; Pawelec G
Front Immunol; 2020; 11():369. PubMed ID: 32210966
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in colorectal cancer: current achievements and future perspective.
Fan A; Wang B; Wang X; Nie Y; Fan D; Zhao X; Lu Y
Int J Biol Sci; 2021; 17(14):3837-3849. PubMed ID: 34671202
[TBL] [Abstract][Full Text] [Related]
9. Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature.
San-Román-Gil M; Martínez-Delfrade I; Albarrán-Fernández V; Guerrero-Serrano P; Pozas-Pérez J; Chamorro-Pérez J; Rosero-Rodríguez D; Sotoca-Rubio P; Barrill-Corpa AM; Alia-Navarro V; González-Merino C; García-de-Quevedo-Suero C; López V; Ruz-Caracuel I; Perna-Monroy C; Ferreiro-Monteagudo R
Front Immunol; 2024; 15():1352262. PubMed ID: 38361927
[TBL] [Abstract][Full Text] [Related]
10. Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients.
Wang D; Zhang H; Xiang T; Wang G
Front Immunol; 2021; 12():762341. PubMed ID: 34721435
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.
Xiao BY; Zhang X; Cao TY; Li DD; Jiang W; Kong LH; Tang JH; Han K; Zhang CZ; Mei WJ; Xiao J; Pan ZZ; Li YF; Zhang XS; Ding PR
J Natl Compr Canc Netw; 2023 Jan; 21(1):60-66.e5. PubMed ID: 36630898
[TBL] [Abstract][Full Text] [Related]
12. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
Front Immunol; 2022; 13():913483. PubMed ID: 35958603
[TBL] [Abstract][Full Text] [Related]
14. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
Almquist DR; Ahn DH; Bekaii-Saab TS
BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
[TBL] [Abstract][Full Text] [Related]
15. Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions.
Pan W; Zhao J; Zhang S; Chen X; Liang W; Li Q
Int Immunopharmacol; 2021 Dec; 101(Pt B):108337. PubMed ID: 34775366
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?
Zhu J; Lian J; Xu B; Pang X; Ji S; Zhao Y; Lu H
Front Immunol; 2023; 14():1120684. PubMed ID: 36949951
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?
Huyghe N; Baldin P; Van den Eynde M
Gastroenterol Rep (Oxf); 2020 Feb; 8(1):11-24. PubMed ID: 32104582
[TBL] [Abstract][Full Text] [Related]
18. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
19. [Neoadjuvant immunotherapy for colorectal cancer].
Pei JP; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):58-67. PubMed ID: 36650001
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review.
Chakrabarti S; Grewal US; Vora KB; Parikh AR; Almader-Douglas D; Mahipal A; Sonbol MBB
JCO Precis Oncol; 2023 Aug; 7():e2300182. PubMed ID: 37595183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
